The adenosine neuromodulation system in schizophrenia

International Review of Neurobiology

Volumn 119, Issue , 2014, Pages 395-449

  Rial, Daniel ^a   Lara, Diogo R ^b   Cunha, Rodrigo A ^a,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Adenosine; Adenosine receptors; Schizophrenia; Working memory

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ALLOPURINOL; AMISULPRIDE; CAFFEINE; CLOZAPINE; DIPYRIDAMOLE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EXCITATORY AMINO ACID TRANSPORTER 1; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NITROPRUSSIDE SODIUM; OLANZAPINE; OMEGA 3 FATTY ACID; SYNAPTOPHYSIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; VESICULAR GLUTAMATE TRANSPORTER 1; ADENOSINE RECEPTOR; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; PURINERGIC RECEPTOR AFFECTING AGENT;

ADENOSINE NEUROMODULATION SYSTEM; ARTICLE; BEHAVIOR; BEHAVIORAL SENSITIZATION; BRAIN MATURATION; CATECHOLAMINERGIC SYSTEM; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; COMORBIDITY; CONNECTOME; DISEASE ASSOCIATION; DISEASE MODEL; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; ENDOPHENOTYPE; GABAERGIC SYSTEM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GLIA CELL; GLUTAMATE SYSTEM; HUMAN; MOLECULAR DYNAMICS; MORPHOLOGY; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; ONSET AGE; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSITIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; STARTLE REFLEX; SYNAPTIC TRANSMISSION; WORKING MEMORY; ANIMAL; METABOLISM;

ADENOSINE; ANIMALS; HUMANS; NEUROTRANSMITTER AGENTS; PURINERGIC AGENTS; RECEPTORS, PURINERGIC P1; SCHIZOPHRENIA;

EID: 84906733813     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-801022-8.00016-7     Document Type: Chapter

References (438)

1. Abbracchio M.P., Fogliatto G., Paoletti A.M., Rovati G.E., Cattabeni F. Prolonged in vitro exposure of rat brain slices to adenosine analogues: Selective desensitization of adenosine A1 but not A2 receptors. European Journal of Pharmacology 1992, 227(3):317-324.
2. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:8104-8109.
3. Achim A.M., Maziade M., Raymond E., Olivier D., Mérette C., Roy M.A. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on asignificant association. Schizophrenia Bulletin 2011, 37:811-821.
4. Adén U., Halldner L., Lagercrantz H., Dalmau I., Ledent C., Fredholm B.B. Aggravated brain damage after hypoxic ischemia in immature adenosine A2A knockout mice. Stroke 2003, 34(3):739-744.
5. 1 receptor agonism in the immature rat brain and heart. European Journal of Pharmacology 2001, 426(3):185-192.
6. Agnati L.F., Fuxe K., Zini I., Lenzi P., Hokfelt T. Aspects on receptor regulation and isoreceptor identification. Medical Biology 1980, 58:182-187.
7. Akhondzadeh S., Safarcherati A., Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: A double blind, randomized and placebo controlled trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2005, 29(2):253-259.
8. Akhondzadeh S., Shasavand E., Jamilian H., Shabestari O., Kamalipour A. Dipyridamole in the treatment of schizophrenia: Adenosine-dopamine receptor interactions. Journal of Clinical Pharmacy and Therapeutics 2000, 25:131-137.
9. Albasanz J.L., Perez S., Barrachina M., Ferrer I., Martín M. Up-regulation of adenosine receptors in the frontal cortex in Alzheimer's disease. Brain Pathology 2008, 18(2):211-219.
10. Albasanz J.L., Rodríguez A., Ferrer I., Martín M. Adenosine A2A receptors are up-regulated in Pick's disease frontal cortex. Brain Pathology 2006, 16(4):249-255.
11. Albasanz J.L., Rodríguez A., Ferrer I., Martín M. Up-regulation of adenosine A1 receptors in frontal cortex from Pick's disease cases. European Journal of Neuroscience 2007, 26(12):3501-3508.
12. 2A receptors. Neuroscience 2011, 190:103-111.
13. Aliagas E., Villar-Menéndez I., Sévigny J., Roca M., Romeu M., Ferrer I., et al. Reduced striatal ecto-nucleotidase activity in schizophrenia patients supports the "adenosine hypothesis". Purinergic Signal 2013, 9(4):599-608.
14. Amann L.C., Gandal M.J., Halene T.B., Ehrlichman R.S., White S.L., McCarren H.S., et al. Mouse behavioral endophenotypes for schizophrenia. Brain Research Bulletin 2010, 83:147-161.
15. Ambrósio A.F., Malva J.O., Carvalho A.P., Carvalho C.M. Inhibition of N-, P/Q- and other types of Ca2+ channels in rat hippocampal nerve terminals by the adenosine A1 receptor. European Journal of Pharmacology 1997, 340(2-3):301-310.
16. Amminger G.P., Schäfer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Archives of General Psychiatry 2010, 67:146-154.
17. Andersen M.B., Fuxe K., Werge T., Gerlach J. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys. Behavioral Pharmacology 2002, 13(8):639-644.
18. Angulo E., Casadó V., Mallol J., Canela E.I., Viñals F., Ferrer I., et al. A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathology 2003, 13(4):440-451.
19. B receptor agonist baclofen. Neuropsychopharmacology 2008, 33:3164-3175.
20. Asghari A.A., Azarnia M., Mirnajafi-Zadeh J., Javan M. Adenosine A1 receptor agonist, N6-cyclohexyladenosine, protects myelin and induces remyelination in an experimental model of rat optic chiasm demyelination; electrophysiological and histopathological studies. Journal of the Neurological Sciences 2013, 325(1-2):22-28.
21. Augusto E., Matos M., Sévigny J., El-Tayeb A., Bynoe M.S., Muller C.E., et al. Ecto-5'-nucleotidase (CD73)-mediated formation of adenosine is critical for the striatal adenosine A2A receptor functions. Journal of Neuroscience 2013, 33:11390-11399.
22. 2A-D2 receptor heteromerization. Neuropsychopharmacology 2009, 34:972-986.
23. Back S.A., Craig A., Luo N.L., Ren J., Akundi R.S., Ribeiro I., et al. Protective effects of caffeine on chronic hypoxia-induced perinatal white matter injury. Annals of Neurology 2006, 60(6):696-705.
24. Bakshi V.P., Geyer M.A., Taaid N., Swerdlow N.R. A comparison of the effects of amphetamine, strychnine and caffeine on prepulse inhibition and latent inhibition. Behavioral Pharmacology 1995, 6(8):801-809.
25. Barksdale K.A., Lahti A.C., Roberts R.C. Synaptic proteins in the postmortem anterior cingulate cortex in schizophrenia: Relationship to treatment and treatment response. Neuropsychopharmacology 2014.
26. 2a receptors in the nucleus accumbens mediate locomotor depression. Brain Research Bulletin 1993, 31:397-404.
27. 2A receptors in amphetamine sensitization. Neuropsychopharmacology 2005, 30:891-900.
28. Bauer D., Haroutunian V., Meador-Woodruff J.H., McCullumsmith R.E. Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia. Schizophrenia Research 2010, 117:92-98.
29. Bekar L., Libionka W., Tian G.F., Xu Q., Torres A., Wang X., et al. Adenosine is crucial for deep brain stimulation-mediated attenuation of tremor. Nature Medicine 2008, 14(1):75-80.
30. Bellesi M., Melone M., Gubbini A., Battistacci S., Conti F. GLT-1 upregulation impairs prepulse inhibition of the startle reflex in adult rats. Glia 2009, 57:703-713.
31. Benarroch E.E. Na+, K+-ATPase: Functions in the nervous system and involvement in neurologic disease. Neurology 2011, 76:287-293.
32. Benes F.M., Davidson J., Bird E.D. Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. Archives of General Psychiatry 1986, 43:31-35.
33. Berghuis P., Rajnicek A.M., Morozov Y.M., Ross R.A., Mulder J., Urbán G.M., et al. Hardwiring the brain: Endocannabinoids shape neuronal connectivity. Science 2007, 316:1212-1216.
34. Beste C., Stock A.K., Ness V., Epplen J.T., Arning L. Differential effects of ADORA2A gene variations in pre-attentive visual sensory memory subprocesses. European Neuropsychopharmacology 2012, 22(8):555-561.
35. Bibbiani F., Oh J.D., Petzer J.P., Castagnoli N., Chen J.F., Schwarzschild M.A., et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Experimental Neurology 2003, 184:285-294.
36. 2A Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's Disease. Parkinson's Disease 2012, 2012:591094.
37. Blennow K., Davidsson P., Gottfries C.G., Ekman R., Heilig M. Synaptic degeneration in thalamus in schizophrenia. Lancet 1996, 348:692-693.
38. Boison D. Adenosine kinase: Exploitation for therapeutic gain. Pharmacological Reviews 2013, 65(3):906-943.
39. Boison D., Chen J.F., Fredholm B.B. Adenosine signaling and function in glial cells. Cell Death and Differentiation 2010, 17(7):1071-1082.
40. Boison D., Singer P., Shen H.Y., Feldon J., Yee B.K. Adenosine hypothesis of schizophrenia-opportunities for pharmacotherapy. Neuropharmacology 2012, 62(3):1527-1543.
41. Boksa P. Animal models of obstetric complications in relation to schizophrenia. Brain Research Reviews 2004, 45(1):1-17.
42. Boksa P. Abnormal synaptic pruning in schizophrenia: Urban myth or reality?. Journal of Psychiatry & Neuroscience 2012, 37:75-77.
43. Bona E., Adén U., Gilland E., Fredholm B.B., Hagberg H. Neonatal cerebral hypoxia-ischemia: The effect of adenosine receptor antagonists. Neuropharmacology 1997, 36(9):1327-1338.
44. Borota D., Murray E., Keceli G., Chang A., Watabe J.M., Ly M., et al. Post-study caffeine administration enhances memory consolidation in humans. Nature Neuroscience 2014, 17:201-203.
45. 2A agonist modulation of D2 agonist-induced β-arrestin2 recruitment. Journal of Molecular Biology 2011, 406:687-699.
46. Borycz J., Pereira M.F., Melani A., Rodrigues R.J., Köfalvi A., Panlilio L., et al. Differential glutamate-dependent and glutamate-independent adenosine A1 receptor-mediated modulation of dopamine release in different striatal compartments. Journal of Neurochemistry 2007, 101:355-363.
47. Bowie C.R., Harvey P.D. Cognition in schizophrenia: Impairments, determinants, and functional importance. The Psychiatric Clinics of North America 2005, 28(613-633):626.
48. Boy C., Meyer P.T., Kircheis G., Holschbach M.H., Herzog H., Elmenhorst D., et al. Cerebral A1 adenosine receptors (A1AR) in liver cirrhosis. European Journal of Nuclear Medicine and Molecular Imaging 2008, 35(3):589-597.
49. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Archives of General Psychiatry 1990, 47:181-188.
50. Braff D., Stone C., Callaway E., Geyer M., Glick I., Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 1978, 15:339-343.
51. Brambilla P., Perez J., Barale F., Schettini G., Soares J.C. GABAergic dysfunction in mood disorders. Molecular Psychiatry 2003, 8(8):721-737. 715.
52. Bromet E.J., Fennig S. Epidemiology and natural history of schizophrenia. Biological Psychiatry 1999, 46:871-881.
53. Brown R.M., Short J.L., Cowen M.S., Ledent C., Lawrence A.J. A differential role for the adenosine A2A receptor in opiate reinforcement vs opiate-seeking behavior. Neuropsychopharmacology 2009, 34(4):844-856.
54. Browning M.D., Dudek E.M., Rapier J.L., Leonard S., Freedman R. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics. Biological Psychiatry 1993, 34:529-535.
55. Brunstein M.G., Ghisolfi E.S., Ramos F.L., Lara D.R. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. Journal of Clinical Psychiatry 2005, 66(2):213-219.
56. Calon F., Dridi M., Hornykiewicz O., Bédard P.J., Rajput A.H., Di Paolo T. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004, 127(Pt 5):1075-1084.
57. Canas P.M., Duarte J.M.N., Rodrigues R.J., Köfalvi A., Cunha R.A. Modification upon aging of the density of presynaptic modulation systems in the hippocampus. Neurobiology of Aging 2009, 30:1877-1884.
58. Canas P.M., Porciúncula L.O., Cunha G.M.A., Silva C.G., Machado N.J., Oliveira J.M.A., et al. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by β-amyloid peptides via p38 mitogen-activated protein kinase pathway. Journal of Neuroscience 2009, 29:14741-14751.
59. Caporale N., Dan Y. Spike timing-dependent plasticity: A Hebbian learning rule. Annual Review of Neuroscience 2008, 31:25-46.
60. Carlson G.C., Talbot K., Halene T.B., Gandal M.J., Kazi H.A., Schlosser L., et al. Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:962-970.
61. Caroni P., Donato F., Muller D. Structural plasticity upon learning: Regulation and functions. Nature Reviews. Neuroscience 2012, 13(7):478-490.
62. Casadó V., Mallol J., Lluis C., Franco R., Canela E.I. Adenosine receptors in myelin fractions and subfractions: The effect of the agonist (R)-phenylisopropyladenosine on myelin membrane microviscosity. Journal of Neurochemistry 1991, 57(5):1623-1629.
63. Castillo M.A., Ghose S., Tamminga C.A., Ulery-Reynolds P.G. Deficits in syntaxin 1 phosphorylation in schizophrenia prefrontal cortex. Biological Psychiatry 2010, 67:208-216.
64. Castner S.A., Goldman-Rakic P.S., Williams G.V. Animal models of working memory: Insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology 2004, 174:111-125.
65. Cerimele J.M., Stern A.P., Jutras-Aswad D. Psychosis following excessive ingestion of energy drinks in a patient with schizophrenia. The American Journal of Psychiatry 2010, 167:353.
66. Chakrabarti S., Freedman J.E. Dipyridamole, cerebrovascular disease, and the vasculature. Vascular Pharmacology 2008, 48(4-6):143-149.
67. Chambers J.S., Thomas D., Saland L., Neve R.L., Perrone-Bizzozero N.I. Growth-associated protein 43 (GAP-43) and synaptophysin alterations in the dentate gyrus of patients with schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2005, 29:283-290.
68. Chang L., Friedman J., Ernst T., Zhong K., Tsopelas N.D., Davis K. Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: Implication for glial dysfunction. Biological Psychiatry 2007, 62:1396-1404.
69. Chen J.F., Eltzschig H.K., Fredholm B.B. Adenosine receptors as drug targets-What are the challenges?. Nature Reviews. Drug Discovery 2013, 12(4):265-286.
70. 2A receptors in neuroadaptation to repeated dopaminergic stimulation: Implications for the treatment of dyskinesias in Parkinson's disease. Neurology 2003, 61(Suppl 6):S74-S81.
71. Chen J.F., Sonsalla P.K., Pedata F., Melani A., Domenici M.R., Popoli P., et al. Adenosine A2A receptors and brain injury: Broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Progress in Neurobiology 2007, 83(5):310-331.
72. Cheng M.C., Lu C.L., Luu S.U., Tsai H.M., Hsu S.H., Chen T.T., et al. Genetic and functional analysis of the DLG4 gene encoding the post-synaptic density protein 95 in schizophrenia. PLoS One 2010, 5:e15107.
73. Cheng H.C., Shih H.M., Chern Y. Essential role of cAMP-response element-binding protein activation by A2A adenosine receptors in rescuing the nerve growth factor-induced neurite outgrowth impaired by blockage of the MAPK cascade. The Journal of Biological Chemistry 2002, 277(37):33930-33942.
74. Cirillo M.A., Seidman L.J. Verbal declarative memory dysfunction in schizophrenia: From clinical assessment to genetics and brain mechanisms. Neuropsychology Review 2003, 13:43-77.
75. Ciruela F., Burgueno J., Casado V., Canals M., Marcellino D., Goldberg S.R., et al. Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Analytical Chemistry 2004, 76:5354-5363.
76. Ciruela F., Casadó V., Rodrigues R.J., Lujan R., Burgueño J., Canals M., et al. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. Journal of Neuroscience 2006, 26:2080-2087.
77. Cognato G.P., Agostinho P.M., Hockemeyer J., Müller C.E., Souza D.O., Cunha R.A. Caffeine and adenosine A2A receptor antagonists prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life. Journal of Neurochemistry 2010, 112:453-462.
78. [U+2082]A receptors inhibit delayed rectifier potassium currents and cell differentiation in primary purified oligodendrocyte cultures. Neuropharmacology 2013, 73:301-310.
79. Costenla A.R., Diógenes M.J., Canas P.M., Rodrigues R.J., Nogueira C., Maroco J., et al. Enhanced role of adenosine A2A receptors in the modulation of LTP in the rat hippocampus upon aging. European Journal of Neuroscience 2011, 34:12-21.
80. Cotter D.R., Pariante C.M., Everall I.P. Glial cell abnormalities in major psychiatric disorders: The evidence and implications. Brain Research Bulletin 2001, 55:585-595.
81. Coyle J.T., Basu A., Benneyworth M., Balu D., Konopaske G. Glutamatergic synaptic dysregulation in schizophrenia: Therapeutic implications. Handbook of Experimental Pharmacology 2012, 213:267-295.
82. Crump C., Winkleby M.A., Sundquist K., Sundquist J. Comorbidities and mortality in persons with schizophrenia: A Swedish national cohort study. The American Journal of Psychiatry 2013, 170:324-333.
83. Cunha R.A. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: Different roles, different sources and different receptors. Neurochemistry International 2001, 38:107-125.
84. Cunha R.A. Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade. Purinergic Signalling 2005, 1:111-134.
85. Cunha R.A., Agostinho P.M. Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. Journal of Alzheimer Disease 2010, 20(Supplement 1):95-116.
86. Cunha R.A., Almeida T., Ribeiro J.A. Parallel modification of adenosine extracellular metabolism and modulatory action in the hippocampus of aged rats. Journal of Neurochemistry 2001, 76:372-382.
87. Cunha G.M.A., Canas P.M., Oliveira C.R., Cunha R.A. Increased density and synapto-protective effect of adenosine A2A receptors upon sub-chronic restraint stress. Neuroscience 2006, 141:1775-1781.
88. Cunha R.A., Correia-de-Sá P., Sebastião A.M., Ribeiro J.A. Preferential activation of excitatory adenosine receptors at rat hippocampal and neuromuscular synapses by adenosine formed from released adenine nucleotides. British Journal of Pharmacology 1996, 119:253-260.
89. Cunha R.A., Vizi E.S., Ribeiro J.A., Sebastião A.M. Preferential release of ATP and its extracellular catabolism as a source of adenosine upon high- but not low-frequency stimulation of rat hippocampal slices. Journal of Neurochemistry 1996, 67:2180-2187.
90. d'Alcantara P., Ledent C., Swillens S., Schiffmann S.N. Inactivation of adenosine A2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission. Neuroscience 2001, 107(3):455-464.
91. 2A receptor regulation of neuroinflammation and traumatic brain injury. Journal of Neuroscience 2010, 30(16):5802-5810.
92. Daré E., Schulte G., Karovic O., Hammarberg C., Fredholm B.B. Modulation of glial cell functions by adenosine receptors. Physiology & Behavior 2007, 92(1-2):15-20.
93. Davidsson P., Gottfries J., Bogdanovic N., Ekman R., Karlsson I., Gottfries C.G., et al. The synaptic-vesicle-specific proteins rab3a and synaptophysin are reduced in thalamus and related cortical brain regions in schizophrenic brains. Schizophrenia Research 1999, 40:23-29.
94. de Bartolomeis A., Fiore G., Iasevoli F. Dopamine-glutamate interaction and antipsychotics mechanism of action: Implication for new pharmacological strategies in psychosis. Current Pharmaceutical Design 2005, 11(27):3561-3594.
95. de Bartolomeis A., Latte G., Tomasetti C., Iasevoli F. Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: Relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches. Molecular Neurobiology 2014, 49:484-511.
96. 2A receptors in schizophrenia. Neuroreport 2003, 14(3):313-316.
97. Deckert J., Nöthen M.M., Rietschel M., Wildenauer D., Bondy B., Ertl M.A., et al. Human adenosine A2a receptor (A2aAR) gene: System- atic mutation screening in patients with schizophrenia. Journal of Neural Transmission 1996, 103:1447-1455.
98. De Freitas B., Schwartz G. Effects of caffeine in chronic psychiatric patients. The American Journal of Psychiatry 1979, 136:1337-1338.
99. DeLisi L.E. The concept of progressive brain change in schizophrenia: Implications for understanding schizophrenia. Schizophrenia Bulletin 2008, 34:312-321.
100. de Mendonça A., Sebastião A.M., Ribeiro J.A. Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor activation. Neuroreport 1995, 6(8):1097-1100.
101. de Mendonça A., Sebastião A.M., Ribeiro J.A. Adenosine: Does it have a neuroprotective role after all?. Brain Research Reviews 2000, 33(2-3):258-274.
102. Deng X., Shibata H., Ninomiya H., Tashiro N., Iwata N., Ozaki N., et al. Association study of polymorphisms in the excitatory amino acid transporter 2 gene (SLC1A2) with schizophrenia. BMC Psychiatry 2004, 4:21.
103. 2A receptors. Hippocampus 2012, 22(2):276-291.
104. Dias R.B., Rombo D.M., Ribeiro J.A., Henley J.M., Sebastiao A.M. Adenosine: Setting the stage for plasticity. Trends in Neurosciences 2013, 36:248-257.
105. Dickerson F.B., Stallings C.R., Origoni A.E., Sullens A., Khushalani S., Sandson N., et al. A double-blind trial of adjunctive allopurinol for schizophrenia. Schizophrenia Research 2009, 109(1-3):66-69.
106. Domschke K., Gajewska A., Winter B., Herrmann M.J., Warrings B., Mühlberger A., et al. ADORA2A Gene variation, caffeine, and emotional processing: A multi-level interaction on startle reflex. Neuropsychopharmacology 2012, 37(3):759-769.
107. Dratcu L., Grandison A., McKay G., Bamidele A., Vasudevan V. Clozapine-resistant psychosis, smoking, and caffeine: Managing the neglected effects of substances that our patients consume every day. American Journal of Therapeutics 2007, 14:314-318.
108. Duarte J.M.N., Agostinho P.M., Carvalho R.A., Cunha R.A. Caffeine consumption prevents diabetes-induced memory impairment and synaptotoxicity in the hippocampus of NONcNZO10/LtJ diabetic mice. PLoS One 2012, 7:e21899.
109. Duarte J.M.N., Carvalho R.A., Cunha R.A., Gruetter R. Caffeine consumption attenuates neurochemical modifications in the hippocampus of streptozotocin-induced diabetic rats. Journal of Neurochemistry 2009, 111:368-379.
110. Duncan L.E., Holmans P.A., Lee P.H., O'Dushlaine C.T., Kirby A.W., Smoller J.W., et al. Pathway analyses implicate glial cells in schizophrenia. PLoS One 2014, 9:e89441.
111. Dunwiddie T.V., Haas H.L. Adenosine increases synaptic facilitation in the in vitro rat hippocampus: Evidence for a presynaptic site of action. Journal Physiology 1985, 369:365-377.
112. Dunwiddie T.V., Masino S.A. The role and regulation of adenosine in the central nervous system. Annual Review of Neuroscience 2001, 24:31-55.
113. Dzamba D., Honsa P., Anderova M. NMDA Receptors in glial cells: Pending questions. Current Neuropharmacology 2013, 11(3):250-262.
114. Elvevag B., Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Critical Reviews in Neurobiology 2000, 14:1-21.
115. Erlenmeyer-Kimling L., Rock D., Roberts S.A., Janal M., Kestenbaum C., Cornblatt B., et al. Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: The New York High-Risk Project. The American Journal of Psychiatry 2000, 157:1416-1422.
116. Espinosa J., Rocha A., Nunes F., Costa M.S., Schein V., Kazlauckas V., et al. Caffeine consumption prevents memory impairment, neuronal damage and adenosine A2a receptors up-regulation in the hippocampus of a rat model of sporadic dementia. Journal of Alzheimer Disease 2013, 34:509-518.
117. Fattorini G., Melone M., Bragina L., Candiracci C., Cozzi A., Pellegrini-Giampietro D.E., et al. GLT-1 expression and Glu uptake in rat cerebral cortex are increased by phencyclidine. Glia 2008, 56:1320-1327.
118. Featherstone R.E., Kapur S., Fletcher P.J. The amphetamine-induced sensitized state as a model of schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2007, 31(8):1556-1571.
119. Fedele D.E., Li T., Lan J.Q., Fredholm B.B., Boison D. Adenosine A1 receptors are crucial in keeping an epileptic focus localized. Experimental Neurology 2006, 200(1):184-190.
120. Feldman D.E. The spike-timing dependence of plasticity. Neuron 2012, 75:556-571.
121. Ferré S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology 1997, 133(2):107-120.
122. Ferré S., Lluís C., Justinova Z., Quiroz C., Orru M., Navarro G., et al. Adenosine-cannabinoid receptor interactions. Implications for striatal function. British Journal of Pharmacology 2010, 160(3):443-453.
123. Ferré S., O'Connor W.T., Snaprud P., Ungerstedt U., Fuxe K. Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience 1994, 63(3):765-773.
124. 2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:7238-7241.
125. Field J.R., Walker A.G., Conn P.J. Targeting glutamate synapses in schizophrenia. Trends in Molecular Medicine 2011, 17:689-698.
126. Fields R.D. Myelination: An overlooked mechanism of synaptic plasticity?. The Neuroscientist 2005, 11:528-531.
127. Fitzgerald P.J. The NMDA receptor may participate in widespread suppression of circuit level neural activity, in addition to a similarly prominent role in circuit level activation. Behavioural Brain Research 2012, 230:291-298.
128. Flaten M.A., Elden A. Caffeine and prepulse inhibition of the acoustic startle reflex. Psychopharmacology 1999, 147(3):322-330.
129. Foussias G., Agid O., Fervaha G., Remington G. Negative symptoms of schizophrenia: Clinical features, relevance to real world functioning and specificity versus other CNS disorders. European Neuropsychopharmacology 2013, 24(5):693-709.
130. 2A adenosine receptors. Journal of Neuroscience 2002, 22:1054-1062.
131. Fredholm B.B., Chen J.F., Cunha R.A., Svenningsson P., Vaugeois J.M. Adenosine and brain function. International Review of Neurobiology 2005, 63:191-270.
132. Fromer M., Pocklington A.J., Kavanagh D.H., Williams H.J., Dwyer S., Gormley P., et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 2014, 506:179-184.
133. 1 receptors using 8-dicyclopropylmethyl-1-[(11)C]methyl-3-propylxanthine PET in Alzheimer's disease. Annals of Nuclear Medicine 2008, 22(10):841-847.
134. Fung S.J., Sivagnanasundaram S., Weickert C.S. Lack of change in markers of presynaptic terminal abundance alongside subtle reductions in markers of presynaptic terminal plasticity in prefrontal cortex of schizophrenia patients. Biological Psychiatry 2011, 69:71-79.
135. Fusar-Poli P., Berger G. Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies. Journal of Clinical Psychopharmacology 2012, 32:179-185.
136. 1/dopamine D1 receptor interactions in the basal ganglia. Brain Research Reviews 1998, 26:258-273.
137. Fuxe K., Stromberg I., Popoli P., Rimondini-Giorgini R., Torvinen M., Ogren S.O., et al. Adenosine receptors and Parkinson's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum. Advances in Neurology 2001, 86:345-353.
138. Gajewska A., Blumenthal T.D., Winter B., Herrmann M.J., Conzelmann A., Mühlberger A., et al. Effects of ADORA2A gene variation and caffeine on prepulse inhibition: A multi-level risk model of anxiety. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2013, 40:115-121.
139. Genovese T., Melani A., Esposito E., Mazzon E., Di Paola R., Bramanti P., et al. The selective adenosine A2A receptor agonist CGS 21680 reduces JNK MAPK activation in oligodendrocytes in injured spinal cord. Shock 2009, 32(6):578-585.
140. Geyer M.A., Braff D.L. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophrenia Bulletin 1987, 13:643-668.
141. Ghisolfi E.S., Prokopiuk A.S., Becker J., Ehlers J.A., Belmonte-de-Abreu P., Souza D.O., et al. The adenosine antagonist theophylline impairs p50 auditory sensory gating in normal subjects. Neuropsychopharmacology 2002, 27(4):629-637.
142. Gimenez-Llort L., Schiffmann S.N., Shmidt T., Canela L., Camon L., Wassholm M., et al. Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain. Neurobiology of Learning and Memory 2007, 87:42-56.
143. 2 receptors for antipsychotic activity. Handbook of Experimental Pharmacology 2012, 212:27-52.
144. Glantz L.A., Gilmore J.H., Lieberman J.A., Jarskog L.F. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophrenia Research 2006, 81:47-63.
145. Goff D.C., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D.A., et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry 1999, 56:21-27.
146. Gogtay N., Rapoport J.L. Childhood-onset schizophrenia: Insights from neuroimaging studies. Journal of the American Academy of Child and Adolescent Psychiatry 2008, 47:1120-1124.
147. Gomes C.A., Ferreira R., George J., Sanches R., Rodrigues D.I., Gonçalves N., et al. Activation of microglial cells triggers a release of brain-derived neurotrophic factor (BDNF) inducing their proliferation in an adenosine A2A receptor-dependent manner. Journal of Neuroinflammation 2013, 10:16.
148. Gomes C.V., Kaster M.P., Tomé A.R., Agostinho P.M., Cunha R.A. Adenosine receptors and brain diseases: Neuroprotection and neurodegeneration. Biochimica et Biophysica Acta - Biomembranes 2011, 1808:1380-1399.
149. Gonçalves N., Simões A.T., Cunha R.A., Pereira de Almeida L. Caffeine and adenosine A2A receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease. Annals of Neurology 2013, 73:655-666.
150. Gonzalez-Burgos G., Lewis D.A. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophrenia Bulletin 2012, 38(5):950-957.
151. 6-cyclopentyladenosine on phencyclidine-induced behavior and expression of the immediate-early genes in the discrete brain regions of rats. Brain Research. Molecular Brain Research 2002, 100(1-2):1-12.
152. Gouder N., Fritschy J.M., Boison D. Seizure suppression by adenosine A1 receptor activation in a mouse model of pharmacoresistant epilepsy. Epilepsia 2003, 44(7):877-885.
153. Goudriaan A., De Leeuw C., Ripke S., Hultman C.M., Sklar P., Sullivan P.F., et al. Specific Glial Functions Contribute to Schizophrenia Susceptibility. Schizophrenia Bulletin 2013, 40(4):925-935.
154. Grabrucker S., Proepper C., Mangus K., Eckert M., Chhabra R., Schmeisser M.J., et al. The PSD protein ProSAP2/Shank3 displays synapto-nuclear shuttling which is deregulated in a schizophrenia-associated mutation. Experimental Neurology 2014, 253:126-137.
155. Grantyn R., Henneberger C., Jüttner R., Meler J.C., Kirischuk S. Functional hallmarks of GABAergic synapse maturation and the diverse roles of neurotrophins. Frontiers in Cellular Neuroscience 2011, 5:1-12.
156. Gray B.E., McMahon R.P., Gold J.M. General intellectual ability does not explain the general deficit in schizophrenia. Schizophrenia Research 2013, 147:315-319.
157. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry 2004, 56:301-307.
158. Greene R. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 2001, 11:569-577.
159. Greene R.W., Haas H.L. Adenosine actions on CA1 pyramidal neurones in rat hippocampal slices. Journal Physiology 1985, 366:119-127.
160. Guilmatre A., Dubourg C., Mosca A.L., Legallic S., Goldenberg A., Drouin-Garraud V., et al. Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. Archives of General Psychiatry 2009, 66:947-956.
161. Gunduz-Bruce H. The acute effects of NMDA antagonism: From the rodent to the human brain. Brain Research Reviews 2009, 60:279-286.
162. Gurpegui M., Aguilar M.C., Martínez-Ortega J.M., Diaz F.J., de Leon J. Caffeine intake in outpatients with schizophrenia. Schizophrenia Bulletin 2004, 30:935-945.
163. Hahn C.G., Wang H.Y., Cho D.S., Talbot K., Gur R.E., Berrettini W.H., et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nature Medicine 2006, 12:824-828.
164. Halassa M.M., Fellin T., Haydon P.G. The tripartite synapse: Roles for gliotransmission in health and disease. Trends in Molecular Medicine 2007, 13:54-63.
165. Halassa M.M., Haydon P.G. Integrated brain circuits: Astrocytic networks modulate neuronal activity and behavior. Annual Review of Physiology 2010, 72:335-355.
166. Hallak J.E., Maia-de-Oliveira J.P., Abrao J., Evora P.R., Zuardi A.W., Crippa J.A., et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: A randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 2013, 70:668-676.
167. Haller S., Rodriguez C., Moser D., Toma S., Hofmeister J., Sinanaj I., et al. Acute caffeine administration impact on working memory-related brain activation and functional connectivity in the elderly: A BOLD and perfusion MRI study. Neuroscience 2013, 250:364-371.
168. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: Implications for neurodegenerative disorders. Nature Reviews. Neuroscience 2010, 11(10):682-696.
169. Hashimoto K., Malchow B., Falkai P., Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. European Archives of Psychiatry and Clinical Neuroscience 2013, 263:367-377.
170. 2a receptors in the nucleus accumbens modulate prepulse inhibition of the startle response. Neuroreport 1997, 8:1515-1518.
171. Haugeto O., Ullensvang K., Levy L.M., Chaudhry F.A., Honore T., Nielsen M., et al. Brain glutamate transporter proteins form homomultimers. The Journal of Biological Chemistry 1996, 271:27715-27722.
172. Hedges D.W., Woon F.L., Hoopes S.P. Caffeine-induced psychosis. CNS Spectrums 2009, 14:127-129.
173. Heresco-Levy U. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2003, 27:1113-1123.
174. Hettinger B.D., Leid M., Murray T.F. Cyclopentyladenosine-induced homologous down-regulation of A1 adenosine receptors (A1AR) in intact neurons is accompanied by receptor sequestration but not a reduction in A1AR mRNA expression or G protein alpha-subunit content. Journal of Neurochemistry 1998, 71(1):221-230.
175. 2A adenosine receptors. Nature Neuroscience 2010, 13:958-966.
176. 2A receptors and dopamine D2 receptors. Journal of Biological Chemistry 2002, 277:18091-18097.
177. Hines D.J., Schmitt L.I., Hines R.M., Moss S.J., Haydon P.G. Antidepressant effects of sleep deprivation require astrocyte-dependent adenosine mediated signaling. Translational Psychiatry 2013, 3:e212.
178. Hirota T., Kishi T. Adenosine hypothesis in schizophrenia and bipolar disorder: A systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Schizophrenia Research 2013, 149(1-3):88-95.
179. Hobson B.D., Merritt K.E., Bachtell R.K. Stimulation of adenosine receptors in the nucleus accumbens reverses the expression of cocaine sensitization and cross-sensitization to dopamine D2 receptors in rats. Neuropharmacology 2012, 63(6):1172-1181.
180. Honea R., Crow T.J., Passingham D., Mackay C.E. Regional deficits in brain volume in schizophrenia: A meta-analysis of voxel-based morphometry studies. The American Journal of Psychiatry 2005, 162:2233-2235.
181. Hong C.J., Liu H.C., Liu T.Y., Liao D.L., Tsai S.J. Association studies of the adenosine A2a receptor (1976T>C) genetic polymorphism in Parkinson's disease and schizophrenia. Journal of Neural Transmission 2005, 112:1503-1510.
182. Huerta I., McCullumsmith R.E., Haroutunian V., Giménez-Amaya J.M., Meador-Woodruff J.H. Expression of excitatory amino acid transporter interacting protein transcripts in the thalamus in schizophrenia. Synapse 2006, 59:394-402.
183. Insel T.R. Rethinking schizophrenia. Nature 2010, 468:188-193.
184. Issy A.C., Pedrazzi J.F., Yoneyama B.H., Del-Bel E.A. Critical role of nitric oxide in the modulation of prepulse inhibition in Swiss mice. Psychopharmacology 2014, 231:663-672.
185. Itil T., Keskiner A., Kiremitci N., Holden J.M. Effect of phencyclidine in chronic schizophrenics. Canadian Psychiatric Association Journal 1967, 12(2):209-212.
186. Izquierdo A., Belcher A.M., Scott L., Cazares V.A., Chen J., O'Dell S.J., et al. Reversal-specific learning impairments after a binge regimen of methamphetamine in rats: Possible involvement of striatal dopamine. Neuropsychopharmacology 2010, 35:505-514.
187. Jaarsma D., Sebens J.B., Korf J. Reduction of adenosine A1-receptors in the perforant pathway terminal zone in Alzheimer hippocampus. Neuroscience Letters 1991, 121(1-2):111-114.
188. Javitt D.C. Glutamate and schizophrenia: Phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. International Review of Neurobiology 2007, 78:69-108.
189. Jentsch J.D., Taylor J.R., Elsworth J.D., Redmond D.E., Roth R.H. Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: Involvement in frontostriatal cognitive deficits. Neuroscience 1999, 90:823-832.
190. Jin S., Johansson B., Fredholm B.B. Effects of adenosine A1 and A2 receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices. The Journal of Pharmacology and Experimental Therapeutics 1993, 267(2):801-808.
191. Kadowaki Horita T., Kobayashi M., Mori A., Jenner P., Kanda T. Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology 2013, 230(3):345-352.
192. 2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia. European Journal of Pharmacology 1996, 295:147-154.
193. Kalaria R.N., Sromek S., Wilcox B.J., Unnerstall J.R. Hippocampal adenosine A1 receptors are decreased in Alzheimer's disease. Neuroscience Letters 1990, 118(2):257-260.
194. Kalivas P.W., Pierce R.C., Cornish J., Sorg B.A. A role for sensitization in craving and relapse in cocaine addiction. Journal of Psychopharmacology 1998, 12:49-53.
195. Karoutzou G., Emrich H.M., Dietrich D.E. The myelin-pathogenesis puzzle in schizophrenia: A literature review. Molecular Psychiatry 2008, 13:245-260.
196. Karson C.N., Mrak R.E., Schluterman K.O., Sturner W.Q., Sheng J.G., Griffin W.S. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: A possible neurochemical basis for 'hypofrontality'. Molecular Psychiatry 1999, 4:39-45.
197. Katsel P., Byne W., Roussos P., Tan W., Siever L., Haroutunian V. Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia. Neuropsychopharmacology 2011, 36:1171-1177.
198. Keefe R.S., Harvey P.D. Cognitive impairment in schizophrenia. Handbook of Experimental Pharmacology 2012, 213:11-37.
199. Kenny E.M., Cormican P., Furlong S., Heron E., Kenny G., Fahey C., et al. Excess of rare novel loss-of-function variants in synaptic genes in schizophrenia and autism spectrum disorders. Molecular Psychiatry 2013, in press.
200. Kettenmann H., Hanisch U.K., Noda M., Verkhratsky A. Physiology of microglia. Physiological Reviews 2011, 91(2):461.
201. Kettenmann H., Kirchhoff F., Verkhratsky A. Microglia: New roles for the synaptic stripper. Neuron 2013, 77(1):10-18.
202. Kim M., Yu Z.X., Fredholm B.B., Rivkees S.A. Susceptibility of the developing brain to acute hypoglycemia involving A1 adenosine receptor activation. American Journal of Physiology. Endocrinology and Metabolism 2005, 289(4):E562-E569.
203. Kirischuk S., Parpura V., Verkhratsky A. Sodium dynamics: Another key to astroglial excitability?. Trends in Neurosciences 2012, 35:497-506.
204. Kirov G., Pocklington A.J., Holmans P., Ivanov D., Ikeda M., Ruderfer D., et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Molecular Psychiatry 2012, 17:142-153.
205. Kishi T., Iwata N. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. Journal of Psychiatric Research 2013, 47(9):1143-1149.
206. Kittner B., Rössner M., Rother M. Clinical trials in dementia with propentofylline. Annals of the New York Academy of Sciences 1997, 826:307-316.
207. Koczapski A., Paredes J., Kogan C., Ledwidge B., Higenbottam J. Effects of caffeine on behavior of schizophrenic inpatients. Schizophrenia Bulletin 1989, 15:339-344.
208. Köhr G. NMDA receptor function: Subunit composition versus spatial distribution. Cell and Tissue Research 2006, 326(2):439-446.
209. Kondziella D., Brenner E., Eyjolfsson E.M., Markinhuhta K.R., Carlsson M.L., Sonnewald U. Glial-neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure. Neuropsychopharmacology 2006, 31:1880-1887.
210. Kondziella D., Brenner E., Eyjolfsson E.M., Sonnewald U. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?. Neurochemistry International 2007, 50:291-301.
211. Konopaske G.T., Dorph-Petersen K.A., Sweet R.A., Pierri J.N., Zhang W., Sampson A.R., et al. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biological Psychiatry 2008, 63:759-765.
212. Koppelstaetter F., Poeppel T.D., Siedentopf C.M., Ischebeck A., Verius M., Haala I., et al. Does caffeine modulate verbal working memory processes? An fMRI study. NeuroImage 2008, 39(1):492-499.
213. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry 1994, 51:199-214.
214. Kung L., Conley R., Chute D.J., Smialek J., Roberts R.C. Synaptic changes in the striatum of schizophrenic cases: A controlled postmortem ultrastructural study. Synapse 1998, 28:125-139.
215. Kurokawa K., Mizuno K., Shibasaki M., Ohkuma S. Regulation of ryanodine receptors by dopamine D1 receptors during methamphetamine-induced place conditioning. Journal of Neurochemistry 2010, 115:1206-1214.
216. 3H] CGS21680 binding in the striatum of postmortem brains of chronic schizophrenics. Brain Research 1998, 808:320-323.
217. Kusano Y., Echeverry G., Miekisiak G., Kulik T.B., Aronhime S.N., Chen J.F., et al. Role of adenosine A2 receptors in regulation of cerebral blood flow during induced hypotension. Journal of Cerebral Blood Flow and Metabolism 2010, 30(4):808-815.
218. Ladeby R., Wirenfeldt M., Garcia-Ovejero D., Fenger C., Dissing-Olesen L., Dalmau I., et al. Microglial cell population dynamics in the injured adult central nervous system. Brain Research Reviews 2005, 48(2):196-206.
219. Lane H.Y., Lin C.H., Green M.F., Hellemann G., Huang C.C., Chen P.W., et al. Add-on treatment of benzoate for schizophrenia: A randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry 2013, 70:1267-1275.
220. Lara D.R., Brunstein M.G., Ghisolfi E.S., Lobato M.I., Belmonte-de-Abreu P., Souza D.O. Allopurinol augmentation for poorly responsive schizophrenia. International Clinical Psychopharmacology 2001, 16(4):235-237.
221. Lara D.R., Dall'Igna O.P., Ghisolfi E.S., Brunstein M.G. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2006, 30:617-629.
222. Lara D.R., Souza D.O. Schizophrenia: A purinergic hypothesis. Medical Hypotheses 2000, 54:157-166.
223. Larimore J., Tornieri K., Ryder P.V., Gokhale A., Zlatic S.A., Craige B., et al. The schizophrenia susceptibility factor dysbindin and its associated complex sort cargoes from cell bodies to the synapse. Molecular Biology of the Cell 2011, 22:4854-4867.
224. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. The Quarterly Journal of Nuclear Medicine 1998, 42:211-221.
225. Laruelle M., Gelernter J., Innis R.B. D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene. Molecular Psychiatry 1998, 3:261-265.
226. Lavoie S., Allaman I., Petit J.M., Do K.Q., Magistretti P.J. Altered glycogen metabolism in cultured astrocytes from mice with chronic glutathione deficit; relevance for neuroenergetics in schizophrenia. PLoS One 2011, 6:e22875.
227. Lerner T.N., Horne E.A., Stella N., Kreitzer A.C. Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists. Journal of Neuroscience 2010, 30(6):2160-2164.
228. Lett T.A., Voineskos A.N., Kennedy J.L., Levine B., Daskalakis Z.J. Treating working memory deficits in schizophrenia: A review of the neurobiology. Biological Psychiatry 2014, 75:361-370.
229. Lewis D.A. Inhibitory neurons in human cortical circuits: Substrate for cognitive dysfunction in schizophrenia. Current Opinion in Neurobiology 2013, 26C:22-26.
230. Lewis D.A., Levitt P. Schizophrenia as a disorder of neurodevelopment. Annual Review of Neuroscience 2002, 25:409-432.
231. Li Y.K., Wang F., Wang W., Luo Y., Wu P.F., Xiao J.L., et al. Aquaporin-4 deficiency impairs synaptic plasticity and associative fear memory in the lateral amygdala: Involvement of downregulation of glutamate transporter-1 expression. Neuropsychopharmacology 2012, 37:1867-1878.
232. Lips E.S., Cornelisse L.N., Toonen R.F., Min J.L., Hultman C.M., International Schizophrenia Consortium, et al. Functional gene group analysis identifies synaptic gene groups as risk factor for schizophrenia. Molecular Psychiatry 2012, 17:996-1006.
233. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neurosciences 2008, 31:234-242.
234. Lodge D.J., Grace A.A. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends in Pharmacological Sciences 2011, 32(9):507-513.
235. Lopes L.V., Cunha R.A., Kull B., Fredholm B.B., Ribeiro J.A. Adenosine A2A receptor facilitation of hippocampal synaptic transmission is dependent on tonic A1 receptor inhibition. Neuroscience 2002, 112:319-329.
236. Lopes L.V., Cunha R.A., Ribeiro J.A. Crosstalk between A1 and A2A adenosine receptors in the hippocampus and cortex of young adult and old rats. Journal of Neurophysiology 1999, 82:3196-3203.
237. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drug; sernyl. Archives of Neurology and Psychiatry 1959, 81:363-369.
238. Lucas P.B., Pickar D., Kelsoe J., Rapaport M., Pato C., Hommer D. Effects of the acute administration of caffeine in patients with schizophrenia. Biological Psychiatry 1990, 28:35-40.
239. Luu S.U., Liao H.M., Hung T.W., Liu B.Y., Cheng M.C., Liao D.L., et al. Mutation analysis of adenosine A2a receptor gene and interaction study with dopamine D2 receptor gene in schizophrenia. Psychiatric Genetics 2008, 18(1):43.
240. MacDonald A.W., Schulz S.C. What we know: Findings that every theory of schizophrenia should explain. Schizophrenia Bulletin 2009, 35:93-108.
241. Martin S.J., Grimwood P.D., Morris R.G. Synaptic plasticity and memory: An evaluation of the hypothesis. Annual Review of Neuroscience 2000, 23:649-711.
242. Martire A., Tebano M.T., Chiodi V., Ferreira S.G., Cunha R.A., Köfalvi A., et al. Presynaptic adenosine A2A receptors control cannabinoid CB1 receptor-mediated inhibition of striatal glutamatergic neurotransmission. Journal of Neurochemistry 2011, 116:273-280.
243. Matos M., Augusto E., Agostinho P., Cunha R.A., Chen J.F. Antagonistic interaction between adenosine A2A receptors and Na+/K+-ATPase-α2 controlling glutamate uptake in astrocytes. Journal of Neuroscience 2013, 33:18492-18502.
244. Matos M., Augusto E., Machado N.J., Santos-Rodrigues A., Cunha R.A., Agostinho P. Astrocytic adenosine A2A receptors control the β-amyloid peptide-induced decrease of glutamate uptake. Journal of Alzheimer Disease 2012, 31:555-567.
245. Matos M., Augusto E., Santos-Rodrigues A., Schwarzschild M.A., Chen J.F., Cunha R.A., et al. Adenosine A2A receptors modulate glutamate uptake in cultured astrocytes and gliosomes. Glia 2012, 60:702-716.
246. Matute C., Melone M., Vallejo-Illarramendi A., Conti F. Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia 2005, 49:451-500.
247. Mayo K.M., Falkowski W., Jones C.A. Caffeine: Use and effects in long-stay psychiatric patients. British Journal of Psychiatry 1993, 162:543-545.
248. McGhie A., Chapman J. Disorders of attention and perception in early schizophrenia. The British Journal of Medical Psychology 1961, 34:103-116.
249. McGrath J.J., Burne T.H., Féron F., Mackay-Sim A., Eyles D.W. Developmental vitamin D deficiency and risk of schizophrenia: A 10-year update. Schizophrenia Bulletin 2010, 36:1073-1078.
250. McGrath J., Saha S., Chant D., Welham J. Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews 2008, 30:67-76.
251. Meador-Woodruff J.H., Clinton S.M., Beneyto M., McCullumsmith R.E. Molecular abnormalities of the glutamate synapse in the thalamus in schizophrenia. Annals of the New York Academy of Sciences 2003, 1003:75-93.
252. Melani A., Cipriani S., Vannucchi M.G., Nosi D., Donati C., Bruni P., et al. Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia. Brain 2009, 132(Pt 6):1480-1495.
253. Melone M., Bragina L., Conti F. Clozapine-induced reduction of glutamate transport in the frontal cortex is not mediated by GLAST and EAAC1. Molecular Psychiatry 2003, 8:12-13.
254. Meyer U., Feldon J., Yee B.K. A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophrenia Bulletin 2009, 35(5):959-972.
255. Miller M.W. Effects of alcohol on the generation and migration of cerebral cortical neurons. Science 1986, 233(4770):1308-1311.
256. Mirnics K., Middleton F.A., Marquez A., Lewis D.A., Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000, 28:53-67.
257. Mitterauer B. Nonfunctional glial proteins in tripartite synapses: A pathophysiological model of schizophrenia. The Neuroscientist 2005, 11:192-198.
258. Mitterauer B.J., Kofler-Westergren B. Possible effects of synaptic imbalances on oligodendrocyte-axonic interactions in schizophrenia: A hypothetical model. Frontiers in Psychiatry 2011, 2:15.
259. Moeller F.G., Steinberg J.L., Lane S.D., Kjome K.L., Ma L., Ferre S., et al. Increased Orbitofrontal Brain Activation after Administration of a Selective Adenosine A(2A) Antagonist in Cocaine Dependent Subjects. Frontiers in Psychiatry 2012, 3:44.
260. Moghaddam B., Javitt D. From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012, 37:4-15.
261. Molero Y., Gumpert C., Serlachius E., Lichtenstein P., Walum H., Johansson D., et al. A study of the possible association between adenosine A2A receptor gene polymorphisms and attention-deficit hyperactivity disorder traits. Genes, Brain, and Behavior 2013, 12(3):305-310.
262. Morgan C., Reininghaus U., Reichenberg A., Frissa S., SELCoH Study Team, Hotopf M., et al. Adversity, cannabis use and psychotic experiences: Evidence of cumulative and synergistic effects. The British Journal of Psychiatry 2014, 204:346-353.
263. Mudge J., Miller N.A., Khrebtukova I., Lindquist I.E., May G.D., Huntley J.J., et al. Genomic convergence analysis of schizophrenia: mRNA sequencing reveals altered synaptic vesicular transport in post-mortem cerebellum. PLoS One 2008, 3:e3625.
264. Nagai T., Takuma K., Dohniwa M., Ibi D., Mizoguchi H., Kamei H., et al. Repeated methamphetamine treatment impairs spatial working memory in rats: Reversal by clozapine but not haloperidol. Psychopharmacology 2007, 194:21-32.
265. Nagel J., Schladebach H., Koch M., Schwienbacher I., Muller C.E., Hauber W. Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats. Synapse 2003, 49:279-286.
266. Nagy J.I., Geiger J.D., Staines W.A. Adenosine deaminase and purinergic neuroregulation. Neurochemistry International 1990, 16(3):211-221.
267. Nakazawa K., Zsiros V., Jiang Z., Nakao K., Kolata S., Zhang S., et al. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 2012, 62(3):1574-1583.
268. 11C]fallypride. Synapse 2009, 63:447-461.
269. Neill J.C., Barnes S., Cook S., Grayson B., Idris N.F., McLean S.L., et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism. Pharmacology & Therapeutics 2010, 128:419-432.
270. Ngai A.C., Coyne E.F., Meno J.R., West G.A., Winn H.R. Receptor subtypes mediating adenosine-induced dilation of cerebral arterioles. American Journal of Physiology. Heart and Circulatory Physiology 2001, 280(5):H2329-H2335.
271. Niizato K., Iritani S., Ikeda K., Arai H. Astroglial function of schizophrenic brain: A study using lobotomized brain. Neuroreport 2001, 12:1457-1460.
272. Ning Y.L., Yang N., Chen X., Xiong R.P., Zhang X.Z., Li P., et al. Adenosine A2A receptor deficiency alleviates blast-induced cognitive dysfunction. Journal of Cerebral Blood Flow and Metabolism 2013, 33(11):1789-1798.
273. 2a adenosine receptors. Glia 2002, 39(2):133-147.
274. Nordahl T.E., Salo R., Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review. The Journal of Neuropsychiatry and Clinical Neurosciences 2003, 15:317-325.
275. O'Driscoll C.M., Gorman A.M. Hypoxia induces neurite outgrowth in PC12 cells that is mediated through adenosine A2A receptors. Neuroscience 2005, 131(2):321-329.
276. Oertel-Knöchel V., Knöchel C., Matura S., Rotarska-Jagiela A., Magerkurth J., Prvulovic D., et al. Cortical-basal ganglia imbalance in schizophrenia patients and unaffected first-degree relatives. Schizophrenia Research 2012, 138:120-127.
277. Ohnuma T., Kato H., Arai H., Faull R.L., McKenna P.J., Emson P.C. Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia. Neuroreport 2000, 11:3133-3137.
278. Olabi B., Ellison-Wright I., McIntosh A.M., Wood S.J., Bullmore E., Lawrie S.M. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biological Psychiatry 2011, 70:88-96.
279. Olsson T., Cronberg T., Rytter A., Asztély F., Fredholm B.B., Smith M.L., et al. Deletion of the adenosine A1 receptor gene does not alter neuronal damage following ischaemia in vivo or in vitro. European Journal of Neuroscience 2004, 20(5):1197-1204.
280. 2A receptor mediates microglial process retraction. Nature Neuroscience 2009, 12(7):872-878.
281. Othman T., Yan H., Rivkees S.A. Oligodendrocytes express functional A1 adenosine receptors that stimulate cellular migration. Glia 2003, 44(2):166-172.
282. Ottoni G.L., Lucchese I.C., Martins F., Grillo R.W., Bogo M.R., Lara D.R. Association between 2592C>TINS polymorphism of adeno- sine A2A receptor gene and schizophrenia. Schizophrenia Bulletin 2005, 31:274.
283. Pacher P., Nivorozhkin A., Szabó C. Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol. Pharmacological Reviews 2006, 58(1):87-114.
284. Pandolfo P., Machado N.J., Köfalvi A., Takahashi R.N., Cunha R.A. Caffeine regulates frontocorticostriatal dopamine transporter density and improves attention and cognitive deficits in an animal model of attention deficit hyperactivity disorder. European Neuropsychopharmacology 2013, 23:317-328.
285. Pankratov Y., Lalo U., Verkhratsky A. North RA Vesicular release of ATP at central synapses. Pflügers Archiv 2006, 452(5):589-597.
286. Pantelis C., Yucel M., Wood S.J., Velakoulis D., Sun D., Berger G., et al. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophrenia Bulletin 2005, 31:672-696.
287. Park T.S., Van Wylen D.G., Rubio R., Berne R.M. Increased brain interstitial fluid adenosine concentration during hypoxia in newborn piglet. Journal of Cerebral Blood Flow and Metabolism 1987, 7(2):178-183.
288. Pascual O., Casper K.B., Kubera C., Zhang J., Revilla-Sanchez R., Sul J.Y., et al. Astrocytic purinergic signaling coordinates synaptic networks. Science 2005, 310(5745):113-116.
289. Pathania M., Davenport E.C., Muir J., Sheehan D.F., López-Doménech G., Kittler J.T. The autism and schizophrenia associated gene CYFIP1 is critical for the maintenance of dendritic complexity and the stabilization of mature spines. Translational Psychiatry 2014, 4:e374.
290. Paulson P.E., Camp D.M., Robinson T.E. Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. Psychopharmacology 1991, 103(4):480-492.
291. Pennington K., Beasley C.L., Dicker P., Fagan A., English J., Pariante C.M., et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Molecular Psychiatry 2008, 13:1102-1117.
292. Perea G., Navarrete M., Araque A. Tripartite synapses: Astrocytes process and control synaptic information. Trends in Neurosciences 2009, 32:421-431.
293. Pereira G.S., Rossato J.I., Sarkis J.J., Cammarota M., Bonan C.D., Izquierdo I. Activation of adenosine receptors in the posterior cingulate cortex impairs memory retrieval in the rat. Neurobiology of Learning and Memory 2005, 83:217-223.
294. Pignataro G., Simon R.P., Boison D. Transgenic overexpression of adenosine kinase aggravates cell death in ischemia. Journal of Cerebral Blood Flow and Metabolism 2007, 27(1):1-5.
295. Pires V.A., Pamplona F.A., Pandolfo P., Fernandes D., Prediger R.D., Takahashi R.N. Adenosine receptor antagonists improve short-term object-recognition ability of spontaneously hypertensive rats: A rodent model of attention-deficit hyperactivity disorder. Behavioral Pharmacology 2009, 20(2):134-145.
296. Poleszak E., Malec D. Influence of adenosine receptor agonists and antagonists on amphetamine-induced stereotypy in rats. Polish Journal of Pharmacology 2000, 52:423-429.
297. Poletti S., Radaelli D., Bosia M., Buonocore M., Pirovano A., Lorenzi C., et al. Effect of glutamate transporter EAAT2 gene variants and gray matter deficits on working memory in schizophrenia. Europan Psychiatry 2013, 29(4):219-225.
298. Potter D., Summerfelt A., Gold J., Buchanan R.W. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophrenia Bulletin 2006, 32:692-700.
299. Powell S.B., Weber M., Geyer M.A. Genetic models of sensorimotor gating: Relevance to neuropsychiatric disorders. Current Topics in Behavioral Neurosciences 2012, 12:251-318.
300. Prediger R.D., Fernandes D., Takahashi R.N. Blockade of adenosine A2A receptors reverses short-term social memory impairments in spontaneously hypertensive rats. Behavioural Brain Research 2005, 159(2):197-205.
301. Quarta D., Borycz J., Solinas M., Patkar K., Hockemeyer J., Ciruela F., et al. Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-D-aspartate receptor stimulation. Journal of Neurochemistry 2004, 91(4):873-880.
302. Rajji T.K., Ismail Z., Mulsant B.H. Age at onset and cognition in schizophrenia: Meta-analysis. The British Journal of Psychiatry 2009, 195:286-293.
303. Rajkowska G., Miguel-Hidalgo J.J., Makkos Z., Meltzer H., Overholser J., Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophrenia Research 2002, 57:127-138.
304. Rajkowska G., Selemon L.D., Goldman-Rakic P.S. Neuronal and glial somal size in the prefrontal cortex: A postmortem morphometric study of schizophrenia and Huntington disease. Archives of General Psychiatry 1998, 55:215-224.
305. Ramamoorthi K., Lin Y. The contribution of GABAergic dysfunction to neurodevelopmental disorders. Trends in Molecular Medicine 2011, 17:452-462.
306. Ramlackhansingh A.F., Bose S.K., Ahmed I., Turkheimer F.E., Pavese N., Brooks D.J. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 2011, 76(21):1811-1816.
307. Ranganath C., Minzenberg M.J., Ragland J.D. The cognitive neuroscience of memory function and dysfunction in schizophrenia. Biological Psychiatry 2008, 64:18-25.
308. Rao J.S., Kellom M., Reese E.A., Rapoport S.I., Kim H.W. Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients. Journal of Affective Disorders 2012, 136:63-71.
309. Rao J.S., Kim H.W., Harry G.J., Rapoport S.I., Reese E.A. Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophrenia Research 2013, 147:24-31.
310. Rebola N., Canas P.M., Oliveira C.R., Cunha R.A. Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat. Neuroscience 2005, 132:893-903.
311. Rebola N., Lujan R., Cunha R.A., Mulle C. Long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses: An essential role for adenosine A2A receptors. Neuron 2008, 57:121-134.
312. Rebola N., Pinheiro P.C., Oliveira C.R., Malva J.O., Cunha R.A. Subcellular localization of adenosine A1 receptors in nerve terminals and synapses of the rat hippocampus. Brain Research 2003, 987:49-58.
313. Rebola N., Porciúncula L.O., Lopes L.V., Oliveira C.R., Soares-da-Silva P., Cunha R.A. Long-term effect of convulsive behavior on the density of adenosine A1 and A2A receptors in the rat cerebral cortex. Epilepsia 2005, 46(Suppl.5):159-165.
314. Rebola N., Rodrigues R.J., Lopes L.V., Richardson P.J., Oliveira C.R., Cunha R.A. Adenosine A1 and A2A receptors are co-expressed in pyramidal neurons and co-localized in glutamatergic nerve terminals of the rat hippocampus. Neuroscience 2005, 133:79-83.
315. Rebola N., Sebastião A.M., de Mendonça A., Oliveira C.R., Ribeiro J.A., Cunha R.A. Enhanced adenosine A2A receptor facilitation of synaptic transmission in the hippocampus of aged rats. Journal of Neurophysiology 2003, 90:1295-1303.
316. Rebola N., Simões A.P., Canas P.M., Tomé A.R., Andrade G.M., Barry C.E., et al. Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. Journal of Neurochemistry 2011, 117:100-111.
317. Reichenberg A., Caspi A., Harrington H., Houts R., Keefe R.S.E., Murray R.M., et al. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: A 30-year study. The American Journal of Psychiatry 2010, 167:160-169.
318. 2A agonists: A potential new type of atypical antipsychotic. Neuropsychopharmacology 1997, 17:82-91.
319. 11C]TMSX brain PET study. Journal of Cerebral Blood Flow and Metabolism 2013, 33(9):1394-1401.
320. Rivkees S.A., Wendler C.C. Adverse and protective influences of adenosine on the newborn and embryo: Implications for preterm white matter injury and embryo protection. Pediatric Research 2011, 69(4):271-278.
321. Rivkees S.A., Zhao Z., Porter G., Turner C. Influences of adenosine on the fetus and newborn. Molecular Genetics and Metabolism 2001, 74(1-2):160-171.
322. Roberts R.C., Conley R., Kung L., Peretti F.J., Chute D.J. Reduced striatal spine size in schizophrenia: A postmortem ultrastructural study. Neuroreport 1996, 7:1214-1218.
323. Robinson T.E., Berridge K.C. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Research Reviews 1993, 18:247-291.
324. Rodrigues R.J., Alfaro T.M., Rebola N., Oliveira C.R., Cunha R.A. Co-localization and functional interaction between adenosine A2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. Journal of Neurochemistry 2005, 92:433-441.
325. Rodríguez-Núñez A., Cid E., Rodríguez-García J., Camiña F., Rodríguez-Segade S., Castro-Gago M. Concentrations of nucleotides, nucleosides, purine bases, oxypurines, uric acid, and neuron-specific enolase in the cerebrospinal fluid of children with sepsis. Journal of Child Neurology 2001, 16(9):704-706.
326. Roffman J.L., Lamberti J.S., Achtyes E., Macklin E.A., Galendez G.C., Raeke L.H., et al. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry 2013, 70:481-489.
327. Rosin D.L., Robeva A., Woodard R.L., Guyenet P.G., Linden J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. The Journal of Comparative Neurology 1998, 401(2):163-186.
328. Rothermundt M., Ohrmann P., Abel S., Siegmund A., Pedersen A., Ponath G., et al. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2007, 31:361-364.
329. Roussos P., Haroutunian V. Schizophrenia: Susceptibility genes and oligodendroglial and myelin related abnormalities. Frontiers in Cellular Neuroscience 2014, 8:5.
330. Rudolphi K.A., Schubert P., Parkinson F.E., Fredholm B.B. Adenosine and brain ischemia. Cerebrovascular and Brain Metabolism Reviews 1992, 4(4):346-369.
331. Ruiz A., Sanz J.M., Gonzalez-Calero G., Fernández M., Andrés A., Cubero A., et al. Desensitization and internalization of adenosine A1 receptors in rat brain by in vivo treatment with R-PIA: Involvement of coated vesicles. Biochimica et Biophysica Acta 1996, 1310(1):168-174.
332. Ruiz-Medina J., Ledent C., Carretón O., Valverde O. The A2a adenosine receptor modulates the reinforcement efficacy and neurotoxicity of MDMA. Journal of Psychopharmacology 2011, 25(4):550-564.
333. Rujescu D., Ingason A., Cichon S., Pietiläinen O.P., Barnes M.R., Toulopoulou T., et al. Disruption of the neurexin 1 gene is associated with schizophrenia. Human Molecular Genetics 2009, 18:988-996.
334. Rund B.R., Melle I., Friis S., Larsen T.K., Midboe L.J., Opjordsmoen S., et al. Neurocognitive dysfunction in first-episode psychosis: Correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. The American Journal of Psychiatry 2004, 161:466-472.
335. Sacchi S., Bernasconi M., Martineau M., Mothet J.P., Ruzzene M., Pilone M.S., et al. pLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase: Effect on schizophrenia susceptibility. The Journal of Biological Chemistry 2008, 283:22244-22256.
336. Salimi S., Fotouhi A., Ghoreishi A., Derakhshan M.K., Khodaie-Ardakani M.R., Mohammadi M.R., et al. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008, 32(3):726-732.
337. Sattler R., Rothstein J.D. Regulation and dysregulation of glutamate transporters. Handbook of Experimental Pharmacology 2006, 175:277-303.
338. Saura J., Angulo E., Ejarque A., Casadó V., Tusell J.M., Moratalla R., et al. Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. Journal of Neurochemistry 2005, 95(4):919-929.
339. Sayed Y., Garrison J.M. The dopamine hypothesis of schizophrenia and the antagonistic action of neuroleptic drugs-A review. Psychopharmacology Bulletin 1983, 19:283-288.
340. Schiffmann S.N., Fisone G., Moresco R., Cunha R.A., Ferré S. Adenosine A2A receptors and basal ganglia physiology. Progress in Neurobiology 2007, 83:277-292.
341. Schmitt L.I., Sims R.E., Dale N., Haydon P.G. Wakefulness affects synaptic and network activity by increasing extracellular astrocyte-derived adenosine. Journal of Neuroscience 2012, 32(13):4417-4425.
342. Schnieder T.P., Dwork A.J. Searching for neuropathology: Gliosis in schizophrenia. Biological Psychiatry 2011, 69:134-139.
343. Schoepf D., Uppal H., Potluri R., Heun R. Physical comorbidity and its relevance on mortality in schizophrenia: A naturalistic 12-year follow-up in general hospital admissions. European Archives of Psychiatry and Clinical Neuroscience 2014, 264:3-28.
344. Sebastião A.M., Cunha R.A., de Mendonça A., Ribeiro J.A. Modification of adenosine modulation of synaptic transmission in the hippocampus of aged rats. British Journal of Pharmacology 2000, 131:1629-1634.
345. Seshadri S., Zeledon M., Sawa A. Synapse-specific contributions in the cortical pathology of schizophrenia. Neurobiology of Disease 2013, 53:26-35.
346. Shaban M., Smith R.A., Stone T.W. Adenosine receptor-mediated inhibition of neurite outgrowth from cultured sensory neurons is via an A1 receptor and is reduced by nerve growth factor. Developmental Brain Research 1998, 105(2):167-173.
347. Shan D., Lucas E.K., Drummond J.B., Haroutunian V., Meador-Woodruff J.H., McCullumsmith R.E. Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia. Schizophrenia Research 2013, 144:1-8.
348. Shao L., Vawter M.P. Shared gene expression alterations in schizophrenia and bipolar disorder. Biological Psychiatry 2008, 64:89-97.
349. Shen H.Y., Canas P.M., Garcia-Sanz P., Lan J.Q., Boison D., Moratalla R., et al. Adenosine A2A receptors in striatal glutamatergic terminals and GABAergic neurons oppositely modulate psychostimulant action and DARPP-32 phosphorylation. PLoS One 2013, 8:e80902.
350. Shen H.Y., Coelho J.E., Ohtsuka N., Canas P.M., Day Y.J., Huang Q.Y., et al. A critical role of the adenosine A2A receptor in extra-striatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum- and forebrain-A2A receptor knockouts. Journal of Neuroscience 2008, 28:2970-2975.
351. Shen H.Y., Singer P., Lytle N., Wei C.J., Lan J.Q., Williams-Karnesky R.L., et al. Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. The Journal of Clinical Investigation 2012, 122:2567-2577.
352. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophrenia Research 2001, 49(1-2):1-52.
353. Shenton M.E., Whitford T.J., Kubicki M. Structural neuroimaging in schizophrenia from methods to insights to treatments. Dialogues in Clinical Neuroscience 2010, 12:317-332.
354. 2A receptors in the expression and development of methamphetamine-induced sensitization. European Journal of Pharmacology 2000, 388:249-254.
355. Shin H.K., Park S.N., Hong K.W. Implication of adenosine A2A receptors in hypotension-induced vasodilation and cerebral blood flow autoregulation in rat pial arteries. Life Sciences 2000, 67(12):1435-1445.
356. Sills T.L., Azampanah A., Fletcher P.J. The adenosine A1 receptor agonist N6-cyclopentyladenosine blocks the disruptive effect of phencyclidine on prepulse inhibition of the acoustic startle response in the rat. European Journal of Pharmacology 1999, 369(3):325-329.
357. Sills T.L., Azampanah A., Fletcher P.J. The adenosine A2A agonist CGS 21680 reverses the reduction in prepulse inhibition of the acoustic startle response induced by phencyclidine, but not by apomorphine and amphetamine. Psychopharmacology 2001, 156(2-3):187-193.
358. Silva C.G., Métin C., Fazeli W., Machado N.J., Darmopil S., Launay P.S., et al. Adenosine receptor antagonists including caffeine alter fetal brain development in mice. Science Translational Medicine 2013, 5:59-70.
359. Silva C.G., Porciúncula L.O., Canas P.M., Oliveira C.R., Cunha R.A. Blockade of adenosine A2A receptors prevents staurosporine-induced apoptosis of rat hippocampal neurons. Neurobiology of Disease 2007, 27:182-189.
360. Simões A.P., Duarte J.A., Agasse F., Canas P.M., Tomé A.R., Agostinho P., et al. Blockade of adenosine A2A receptors prevents interleukin-1β-induced exacerbation of neuronal toxicity through a p38 MAPK pathway. Journal of Neuroinflammation 2012, 9:204.
361. Simpson M.D., Slater P., Deakin J.F. Comparison of glutamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia. Biological Psychiatry 1998, 15:423-427.
362. 2A receptor spares latent inhibition and prepulse inhibition but impairs active avoidance learning. Behavioural Brain Research 2013, 242:54-61.
363. Singh S.P., Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 2011, 25:859-885.
364. Smith R.E., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. The American Journal of Psychiatry 2001, 158:1393-1399.
365. Smith D.J., Langan J., McLean G., Guthrie B., Mercer S.W. Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: Cross-sectional study. BMJ Open 2013.
366. Snyder S.H. Dopamine receptors, neuroleptics, and schizophrenia. The American Journal of Psychiatry 1981, 138:460-464.
367. Snyder M.A., Gao W.J. NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Frontiers in Cellular Neuroscience 2013, 7:31.
368. Sørensen H.J., Mortensen E.L., Schiffman J., Reinisch J.M., Maeda J., Mednick S.A. Early developmental milestones and risk of schizophrenia: A 45-year follow-up of the Copenhagen Perinatal Cohort. Schizophrenia Research 2010, 118:41-47.
369. Soria G., Castañé A., Ledent C., Parmentier M., Maldonado R., Valverde O. The lack of A2A adenosine receptors diminishes the reinforcing efficacy of cocaine. Neuropsychopharmacology 2006, 31(5):978-987.
370. Spangaro M., Bosia M., Zanoletti A., Bechi M., Cocchi F., Pirovano A., et al. Cognitive dysfunction and glutamate reuptake- effect of EAAT2 polymorphism in schizophrenia. Neuroscience Letters 2012, 522:151-155.
371. Srisurapanont M., Arunpongpaisal S., Wada K., Marsden J., Ali R., Kongsakon R. Comparisons of methamphetamine psychotic and schizophrenic symptoms: A differential item functioning analysis. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2011, 35:959-964.
372. Stafford M.R., Jackson H., Mayo-Wilson E., Morrison A.P., Kendall T. Early interventions to prevent psychosis: Systematic review and meta-analysis. BMJ 2013, 346:f185.
373. Stark A.K., Uylings H.B., Sanz-Arigita E., Pakkenberg B. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. The American Journal of Psychiatry 2004, 161:882-888.
374. Steffek A.E., McCullumsmith R.E., Haroutunian V., Meador-Woodruff J.H. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophrenia Research 2008, 103:71-82.
375. Steiner J., Bernstein H.G., Bielau H., Farkas N., Winter J., Dobrowolny H., et al. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: A morphometric study. Journal of Psychiatric Research 2008, 42:868-876.
376. Steketee J.D., Kalivas P.W. Drug wanting: Behavioral sensitization and relapse to drug-seeking behavior. Pharmacological Reviews 2011, 63:348-365.
377. Stevens B., Porta S., Haak L.L., Gallo V., Fields R.D. Adenosine: A neuron-glial transmitter promoting myelination in the CNS in response to action potentials. Neuron 2002, 36(5):855-868.
378. Stewart D.G., Davis K.L. Possible contributions of myelin and oligodendrocyte dysfunction to schizophrenia. International Review of Neurobiology 2004, 59:381-424.
379. Stone T.W., Behan W.M. Interleukin-1beta but not tumor necrosis factor-alpha potentiates neuronal damage by quinolinic acid: Protection by an adenosine A2A receptor antagonist. Journal of Neuroscience Research 2007, 85(5):1077-1085.
380. Stoof J.C., Kebabian J.W. Two dopamine receptors: Biochemistry, physiology and pharmacology. Life Sciences 1984, 35:2281-2296.
381. Studer F.E., Fedele D.E., Marowsky A., Schwerdel C., Wernli K., Vogt K., et al. Shift of adenosine kinase expression from neurons to astrocytes during postnatal development suggests dual functionality of the enzyme. Neuroscience 2006, 142(1):125-137.
382. Sun C.N., Chuang H.C., Wang J.Y., Chen S.Y., Cheng Y.Y., Lee C.F., et al. The A2A adenosine receptor rescues neuritogenesis impaired by p53 blockage via KIF2A, a kinesin family member. Developmental Neurobiology 2010, 70(8):604-621.
383. Suzuki A., Stern S.A., Bozdagi O., Huntley G.W., Walker R.H., Magistretti P.J., et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 2011, 144:810-823.
384. Svenningsson P., Le Moine C., Fisone G., Fredholm B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Progress in Neurobiology 1999, 59(4):355-396.
385. Svensson T.H. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Research Reviews 2000, 31(2-3):320-329.
386. Swanson T.H., Drazba J.A., Rivkees S.A. Adenosine A1 receptors are located predominantly on axons in the rat hippocampal formation. The Journal of Comparative Neurology 1995, 363(4):517-531.
387. Swanson T.H., Krahl S.E., Liu Y.Z., Drazba J.A., Rivkees S.A. Evidence for physiologically active axonal adenosine receptors in the rat corpus callosum. Brain Research 1998, 784(1-2):188-198.
388. Swerdlow N.R., Braff D.L., Hartston H., Perry W., Geyer M.A. Latent inhibition in schizophrenia. Schizophrenia Research 1996, 20:91-103.
389. Swerdlow N.R., Eastvold A., Gerbranda T., Uyan K.M., Hartman P., Doan Q., et al. Effects of caffeine on sensorimotor gating of the startle reflex in normal control subjects: Impact of caffeine intake and withdrawal. Psychopharmacology 2000, 151(4):368-378.
390. Talbot K., Louneva N., Cohen J.W., Kazi H., Blake D.J., Arnold S.E. Synaptic dysbindin-1 reductions in schizophrenia occur in an isoform-specific manner indicating their subsynaptic location. PLoS One 2011, 6:e16886.
391. Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophrenia Research 2008, 102:1-18.
392. Thevananther S., Rivera A., Rivkees S.A. A1 adenosine receptor activation inhibits neurite process formation by Rho kinase-mediated pathways. Neuroreport 2001, 12(14):3057-3063.
393. Thoma P., Daum I. Comorbid substance use disorder in schizophrenia: A selective overview of neurobiological and cognitive underpinnings. Psychiatry and Clinical Neurosciences 2013, 67:367-383.
394. Thompson S.M., Haas H.L., Gähwiler B.H. Comparison of the actions of adenosine at pre- and postsynaptic receptors in the rat hippocampus in vitro. Journal Physiology 1992, 451:347-363.
395. Thompson B.L., Levitt P. Now you see it, now you don't-closing in on allostasis and developmental basis of psychiatric disorders. Neuron 2010, 65:437-439.
396. Tian L., Meng C., Yan H., Zhao Q., Liu Q., Yan J., et al. Convergent evidence from multimodal imaging reveals amygdala abnormalities in schizophrenic patients and their first-degree relatives. PLoS One 2011, 6:e28794.
397. Tibrewal P., Dhillon R. Caffeine induced psychotic exacerbation. The Australian and New Zealand Journal of Psychiatry 2011, 45:179-180.
398. Tkachev D., Mimmack M.L., Ryan M.M., Wayland M., Freeman T., Jones P.B., et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362:798-805.
399. Todarello G., Feng N., Kolachana B.S., Li C., Vakkalanka R., Bertolino A., et al. Incomplete penetrance of NRXN1 deletions in families with schizophrenia. Schizophrenia Research 2014.
400. Tomé A.R., Silva H., Cunha R.A. Role of the purinergic neuromodulation system in epilepsy. Open Neuroscience Journal 2010, 4:64-83.
401. 2A and dopamine D2 receptors. Journal of Molecular Neuroscience 2005, 25:191-200.
402. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. D-serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 1998, 44:1081-1089.
403. Turetsky B.I., Calkins M.E., Light G.A., Olincy A., Radant A.D., Swerdlow N.R. Neurophysiological endophenotypes of schizophrenia: The viability of selected candidate measures. Schizophrenia Bulletin 2007, 33(1):69-94.
404. Turner C.P., Seli M., Ment L., Stewart W., Yan H., Johansson B., et al. A1 adenosine receptors mediate hypoxia-induced ventriculomegaly. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(20):11718-11722.
405. Turner C.P., Yan H., Schwartz M., Othman T., Rivkees S.A. A1 adenosine receptor activation induces ventriculomegaly and white matter loss. Neuroreport 2002, 13(9):1199-1204.
406. Turpin G. Effects of stimulus intensity on autonomic responding: The problem of differentiating orienting and defense reflexes. Psychophysiology 1986, 23:1-14.
407. Tzingounis A.V., Wadiche J.I. Glutamate transporters: Confining runaway excitation by shaping synaptic transmission. Nature Reviews. Neuroscience 2007, 8:935-947.
408. Uezato A., Kimura-Sato J., Yamamoto N., Iijima Y., Kunugi H., Nishikawa T. Further evidence for a male-selective genetic association of synapse-associated protein 97 (SAP97) gene with schizophrenia. Behavioral and Brain Functions 2012, 8:2.
409. Ułas J., Brunner L.C., Nguyen L., Cotman C.W. Reduced density of adenosine A1 receptors and preserved coupling of adenosine A1 receptors to G proteins in Alzheimer hippocampus: A quantitative autoradiographic study. Neuroscience 1993, 52(4):843-854.
410. Ulrich D., Huguenard J.R. Purinergic inhibition of GABA and glutamate release in the thalamus: Implications for thalamic network activity. Neuron 1995, 15(4):909-918.
411. Vallejo-Illarramendi A., Torres-Ramos M., Melone M., Conti F., Matute C. Clozapine reduces GLT-1 expression and glutamate uptake in astrocyte cultures. Glia 2005, 50:276-279.
412. van Snellenberg J.X. Working memory and long-term memory deficits in schizophrenia: Is there a common substrate?. Psychiatry Research 2009, 174:89-96.
413. Varese F., Smeets F., Drukker M., Lieverse R., Lataster T., Viechtbauer W., et al. Childhood adversities increase the risk of psychosis: A meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophrenia Bulletin 2012, 38:661-671.
414. Venables P.H. The effect of auditory and visual stimulation on the skin potential response of schizophrenics. Brain 1960, 83:77-92.
415. Verkhratsky A., Kirchhoff F. NMDA Receptors in glia. The Neuroscientist 2007, 13(1):28-37.
416. Verret L., Mann E.O., Hang G.B., Barth A.M., Cobos I., Ho K., et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 2012, 149(3):708-721.
417. Villar-Menéndez I., Díaz-Sánchez S., Blanch M., Albasanz J.L., Pereira-Veiga T., Monje A., et al. Reduced striatal adenosine A2A receptor levels define a molecular subgroup in schizophrenia. Journal of Psychiatric Research 2014, 51:49-59.
418. Volk D.W., Lewis D.A. Prenatal ontogeny as a susceptibility period for cortical GABA neuron disturbances in schizophrenia. Neuroscience 2013, 248C:154-164.
419. Wakade T.D., Palmer K.C., McCauley R., Przywara D.A., Wakade A.R. Adenosine-induced apoptosis in chick embryonic sympathetic neurons: A new physiological role for adenosine. Journal Physiology 1995, 488(Pt 1):123-138.
420. 2A receptors. Experimental Neurology 2006, 199:438-445.
421. 2A receptor. Behavioural Brain Research 2003, 143:201-207.
422. Wardas J. Potential role of adenosine A2A receptors in the treatment of schizophrenia. Frontiers in Bioscience 2008, 13:4071-4096.
423. 2A agonist, on the phencyclidine-induced sensorimotor gating deficit and motor behaviour in rats. Psychopharmacology 2003, 168(3):299-306.
424. Wei C.J., Augusto E., Gomes C.A., Singer P., Wang Y., Boison D., et al. Regulation of fear responses by striatal and extra-striatal adenosine A2A receptors in forebrain. Biological Psychiatry 2013.
425. 2A receptors in striatal neurons enhances working memory and reversal learning. Learning & Memory 2011, 18(7):459-474.
426. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry 1987, 44:660-669.
427. Weis S., Llenos I.C. GFAP-immunopositive astrocytes in schizophrenia. Schizophrenia Research 2004, 67:293-295.
428. White T.D., MacDonald W.F. Neural release of ATP and adenosine. Annals of the New York Academy of Sciences 1990, 603:287-298.
429. Wieraszko A., Goldsmith G., Seyfried T.N. Stimulation-dependent release of adenosine triphosphate from hippocampal slices. Brain Research 1989, 485(2):244-250.
430. Williams M.R., Hampton T., Pearce R.K., Hirsch S.R., Ansorge O., Thom M., et al. Astrocyte decrease in the subgenual cingulate and callosal genu in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 2013, 263:41-52.
431. Wirkner K., Gerevich Z., Krause T., Günther A., Köles L., Schneider D., et al. Adenosine A2A receptor-induced inhibition of NMDA and GABAA receptor-mediated synaptic currents in a subpopulation of rat striatal neurons. Neuropharmacology 2004, 46(7):994-1007.
432. Wonodi I., Gopinath H.V., Liu J., Adami H., Hong L.E., Allen-Emerson R., et al. Dipyridamole monotherapy in schizophrenia: Pilot of a novel treatment approach by modulation of purinergic signaling. Psychopharmacology 2011, 218(2):341-345.
433. Woodberry K.A., Giuliano A.J., Seidman L.J. Premorbid IQ in schizophrenia: A meta-analytic review. The American Journal of Psychiatry 2008, 165:579-587.
434. Xiao D., Bastia E., Xu Y.H., Benn C.L., Cha J.H., Peterson T.S., et al. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. Journal of Neuroscience 2006, 26(52):13548-13555.
435. Yang Z.J., Wang B., Kwansa H., Heitmiller K.D., Hong G., Carter E.L., et al. Adenosine A2A receptor contributes to ischemic brain damage in newborn piglet. Journal of Cerebral Blood Flow and Metabolism 2013, 33(10):1612-1620.
436. Yee B.K., Singer P., Chen J.F., Feldon J., Boison D. Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs. European Journal of Neuroscience 2007, 26(11):3237-3252.
437. Yin D.M., Chen Y.J., Sathyamurthy A., Xiong W.C., Mei L. Synaptic dysfunction in schizophrenia. Advances in Experimental Medicine and Biology 2012, 970:493-516.
438. Zhang J., Abdallah C.G., Wang J., Wan X., Liang C., Jiang L., et al. Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients. Psychiatry Research 2012, 200(2-3):126-132.